From: Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Pred. TTP | Clinic. TTP | |||
---|---|---|---|---|
0–90 days | 90–150 days | 150–365 days | No progressive disease during follow-up | |
0–90 days | 6 (11.1%) | 0 (0%) | 2 (3.7%) | 2 (3.7%) |
90–150 days | 0 (0%) | 2 (3.7%) | 0 (0%) | 3 (5.6%) |
150–365 days | 0 (0%) | 0 (0%) | 1 (1.8%) | 0 (0%) |
No progressive disease during follow-up | 4 (7.4%) | 2 (3.7%) | 2 (3.7%) | 30 (55.6%) |